Virion\Serion

Virion\Serion

Würzburg, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Virion\Serion is a well-established, privately-held German diagnostics company with over 45 years of experience. It has successfully built a dual business model, combining the development of finished IVD test kits with the production of critical raw materials, serving both end-users and other diagnostic manufacturers. The company's strengths lie in its broad infectious disease portfolio, deep expertise in antigen manufacturing, and recent successful transition to the EU's stringent IVDR regulatory framework. Its outlook is stable, supported by a resilient business model and ongoing demand for infectious disease testing.

Infectious Diseases

Technology Platform

Immunoassay-based diagnostics (ELISA, CLIA) with core expertise in high-quality antigen and antibody production for serological testing. Platforms include manual test kits, automated solutions, and software tools.

Opportunities

The successful IVDR certification provides a competitive edge in the EU market against non-compliant players.
The dual business model allows revenue from both end-user test sales and high-margin raw material supply to other diagnostics manufacturers.
Persistent global demand for infectious disease testing offers a stable market foundation.

Risk Factors

Intense competition from large IVD multinationals and potential technological disruption from molecular diagnostics.
Regulatory complexity and cost associated with maintaining IVDR and other global certifications.
Dependence on the continued relevance of serological testing in an evolving diagnostic landscape.

Competitive Landscape

Virion\Serion competes in the fragmented infectious disease diagnostics segment. It faces competition from large, diversified players like Abbott, Roche, and Siemens Healthineers, as well as other specialized serology companies. Its competitive differentiation lies in its exceptionally broad pathogen portfolio, deep antigen manufacturing expertise, and its unique position as both a kit manufacturer and a key raw material supplier.